Clinical trial
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost…
NCT00440141 · Allergan, Industry · Completed
Key facts
| NCT number | NCT00440141 |
|---|---|
| Title | Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005% |
| Lead sponsor | Allergan, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Glaucoma, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | latanoprost 0.005% eye drops and brimonidine 0.1% eye drops, latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops |
| Enrollment | 40 |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Feb 26, 2007 |
| Last update posted | Jan 2, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: